The structural and social determinants of Alzheimer's disease related dementias

Paris B. Adkins-Jackson, Kristen M. George, Lilah M. Besser, Jinshil Hyun, Melissa Lamar, Tanisha G. Hill-Jarrett, Omonigho M. Bubu, Jason D. Flatt, Patricia C. Heyn, Ethan C. Cicero, A. Zarina Kraal, Preeti Pushpalata Zanwar, Rachel Peterson, Boeun Kim, Robert W. Turner, Jaya Viswanathan, Erin R. Kulick, Megan Zuelsdorff, Shana D. Stites, Miguel Arce RenteríaElena Tsoy, Dominika Seblova, Ted K.S. Ng, Jennifer J. Manly, Ganesh Babulal

Research output: Contribution to journalReview articlepeer-review

136 Scopus citations

Abstract

Introduction: The projected growth of Alzheimer's disease (AD) and AD-related dementia (ADRD) cases by midcentury has expanded the research field and impelled new lines of inquiry into structural and social determinants of health (S/SDOH) as fundamental drivers of disparities in AD/ADRD. Methods: In this review, we employ Bronfenbrenner's ecological systems theory as a framework to posit how S/SDOH impact AD/ADRD risk and outcomes. Results: Bronfenbrenner defined the “macrosystem” as the realm of power (structural) systems that drive S/SDOH and that are the root cause of health disparities. These root causes have been discussed little to date in relation to AD/ADRD, and thus, macrosystem influences, such as racism, classism, sexism, and homophobia, are the emphasis in this paper. Discussion: Under Bronfenbrenner's macrosystem framework, we highlight key quantitative and qualitative studies linking S/SDOH with AD/ADRD, identify scientific gaps in the literature, and propose guidance for future research. Highlights: Ecological systems theory links structural/social determinants to AD/ADRD. Structural/social determinants accrue and interact over the life course to impact AD/ADRD. Macrosystem is made up of societal norms, beliefs, values, and practices (e.g., laws). Most macro-level determinants have been understudied in the AD/ADRD literature.

Original languageEnglish
Pages (from-to)3171-3185
Number of pages15
JournalAlzheimer's and Dementia
Volume19
Issue number7
DOIs
StatePublished - Jul 2023

Funding

We would like to thank the entire Alzheimer's Association ISTAART Diversity and Disparities Professional Interest Area (PIA) Structural and SDOH Workgroup for their support. This work was supported by the Columbia University Alzheimer's Disease Resource Centers for Minority Aging Research (RCMAR) [P30AG059303, 2018–2023 (Manly), 2019–2020 pilot (Bubu), 2019–2021 pilot (Arce Rentería), 2022–2023 pilot (Adkins‐Jackson) (Kraal)]; NIA [R01AG052132, 2021–2026 (Whitmer, Glymour, Gilsanz, Mayeda), 2022–2027 (Whitmer, Gilsanz, Corrada)], [RF1AG050782, 2017–2022 (Whitmer)], [K01AG063895, 2020–2025 (Besser)], [R21AG075291, 2022–2024 (Besser)], [K23AG068534, 2021–2026 (Bubu)], [L30‐AG064670, 2019–2023 (Bubu)], [3K01AG054762‐03S1, 2022–2023 (Turner)], [3K01AG054762, 2022–2023 (Turner)], [K01AG056669, 2022–2023 (Flatt)], [R24AG065170, 2022–2023 (Flatt)], [5TR13AG072884‐02 (Heyn PC)], [1R13AG071313‐01, 2021–2024 (Turner, Rivera‐Mindt)], [(K23AG065442, 2020–2024 (Stites)], [R03AG063303, 2019–2022 (Zuelsdorff)], [R01AG062711 (Lamar)], [DP1AG069874, 2020–2024 (Kim)], [1K99AG066932, 2020–2022 (Arce Rentería)], 3K23AG065442‐03S1, 2022–2023 (Stites)], [U24AG058556, 2020–2023 (Stites)], [R01AG074302, 2021–2026 (Babulal)], [R01AG068183, 2020–2025 (Babulal), [R01AG067428, 2020–2025 (Babulal)], [R01AG056466, 2017–2023 (Babulal)]; National Institute of Neurological Disorders and Stroke (NINDS) [R01NS119651, 2022–2023 subward (Turner II)]; California Department of Public Health [RFA 20‐10079, 2022–2024 (Nosheny, Mayeda, George)]; Krueger v. Wyeth Inc. Class Action [2021–2026 (Whitemer)]; New York University Alzheimer's Disease Research Center Developmental Pilot [P30AG066512, 2020–2022 (Bubu)]; BrightFocus Foundation [A2022033S, 2022–2025 (Bubu)], [A2021142S, 2020–2023 (Babulal)]; Harmony Biosciences [Progress at the Heart Program, 2021–2023 subaward (Turner)]; Arizona State University, Center for Innovation in Healthy and Resilient Aging [PG‐14829, pilot (Ng)]; PRIMUS Research Programme [22/MED/012, 2022–2025 (Seblova)]; Alzheimer's Association [AARG‐21‐850963, 2022–2025 (Besser)], [AARG‐D‐21‐848397, 2021–2023 (Bubu)], [AARFD‐22‐924846, 2022–2025 (Kraal)], Alzheimer's Association [Emerging Scholars Program, 2021–2024 (Turner, Rivera‐Mindt)], [AARF‐18‐562958, 2018–2022 (Zuelsdorff)], [AARF‐17‐528934, 2017–2023 (Stites)], [AARFD‐18‐565015, 2018–2022 (Arce Rentería)], [AARF‐21‐851552, 2021–2023 (Tsoy)], [AARF‐21‐848200, 2022–2025 (Seblova)]. We would like to thank the entire Alzheimer's Association ISTAART Diversity and Disparities Professional Interest Area (PIA) Structural and SDOH Workgroup for their support. This work was supported by the Columbia University Alzheimer's Disease Resource Centers for Minority Aging Research (RCMAR) [P30AG059303, 2018–2023 (Manly), 2019–2020 pilot (Bubu), 2019–2021 pilot (Arce Rentería), 2022–2023 pilot (Adkins-Jackson) (Kraal)]; NIA [R01AG052132, 2021–2026 (Whitmer, Glymour, Gilsanz, Mayeda), 2022–2027 (Whitmer, Gilsanz, Corrada)], [RF1AG050782, 2017–2022 (Whitmer)], [K01AG063895, 2020–2025 (Besser)], [R21AG075291, 2022–2024 (Besser)], [K23AG068534, 2021–2026 (Bubu)], [L30-AG064670, 2019–2023 (Bubu)], [3K01AG054762-03S1, 2022–2023 (Turner)], [3K01AG054762, 2022–2023 (Turner)], [K01AG056669, 2022–2023 (Flatt)], [R24AG065170, 2022–2023 (Flatt)], [5TR13AG072884-02 (Heyn PC)], [1R13AG071313-01, 2021–2024 (Turner, Rivera-Mindt)], [(K23AG065442, 2020–2024 (Stites)], [R03AG063303, 2019–2022 (Zuelsdorff)], [R01AG062711 (Lamar)], [DP1AG069874, 2020–2024 (Kim)], [1K99AG066932, 2020–2022 (Arce Rentería)], 3K23AG065442-03S1, 2022–2023 (Stites)], [U24AG058556, 2020–2023 (Stites)], [R01AG074302, 2021–2026 (Babulal)], [R01AG068183, 2020–2025 (Babulal), [R01AG067428, 2020–2025 (Babulal)], [R01AG056466, 2017–2023 (Babulal)]; National Institute of Neurological Disorders and Stroke (NINDS) [R01NS119651, 2022–2023 subward (Turner II)]; California Department of Public Health [RFA 20-10079, 2022–2024 (Nosheny, Mayeda, George)]; Krueger v. Wyeth Inc. Class Action [2021–2026 (Whitemer)]; New York University Alzheimer's Disease Research Center Developmental Pilot [P30AG066512, 2020–2022 (Bubu)]; BrightFocus Foundation [A2022033S, 2022–2025 (Bubu)], [A2021142S, 2020–2023 (Babulal)]; Harmony Biosciences [Progress at the Heart Program, 2021–2023 subaward (Turner)]; Arizona State University, Center for Innovation in Healthy and Resilient Aging [PG-14829, pilot (Ng)]; PRIMUS Research Programme [22/MED/012, 2022–2025 (Seblova)]; Alzheimer's Association [AARG-21-850963, 2022–2025 (Besser)], [AARG-D-21-848397, 2021–2023 (Bubu)], [AARFD-22-924846, 2022–2025 (Kraal)], Alzheimer's Association [Emerging Scholars Program, 2021–2024 (Turner, Rivera-Mindt)], [AARF-18-562958, 2018–2022 (Zuelsdorff)], [AARF-17-528934, 2017–2023 (Stites)], [AARFD-18-565015, 2018–2022 (Arce Rentería)], [AARF-21-851552, 2021–2023 (Tsoy)], [AARF-21-848200, 2022–2025 (Seblova)].

FundersFunder number
P30AG059303
DP1AG069874, U24AG058556, R01AG067428, K01AG063895, K01AG056669, RF1AG050782, 5TR13AG072884‐02, K23AG068534, R03AG063303, R01AG052132, K23AG065442, R01AG056466, R01AG074302, 1K99AG066932, L30-AG064670, R01AG068183, R21AG075291, R24AG065170, 3K01AG054762, R01AG062711, 1R13AG071313‐01
R01NS119651
RFA 20‐10079
A2021142S, A2022033S
P30AG066512
Arizona State University22/MED/012, AARF-17-528934, AARFD-18-565015, AARFD-22-924846, AARF-21-848200, AARF-18-562958, AARG-21-850963, AARG-D-21-848397, PG-14829, AARF-21-851552

    Keywords

    • ADRD
    • Alzheimer's disease
    • Ecological Systems Theory
    • classism
    • dementia
    • genderism
    • macrosystem
    • racism
    • sexism
    • social determinants of health
    • structural determinants
    • Humans
    • Alzheimer Disease
    • Social Determinants of Health
    • Dementia

    Fingerprint

    Dive into the research topics of 'The structural and social determinants of Alzheimer's disease related dementias'. Together they form a unique fingerprint.

    Cite this